SI2913343T1 - Protitelo anti-ILT7 - Google Patents

Protitelo anti-ILT7

Info

Publication number
SI2913343T1
SI2913343T1 SI200632299T SI200632299T SI2913343T1 SI 2913343 T1 SI2913343 T1 SI 2913343T1 SI 200632299 T SI200632299 T SI 200632299T SI 200632299 T SI200632299 T SI 200632299T SI 2913343 T1 SI2913343 T1 SI 2913343T1
Authority
SI
Slovenia
Prior art keywords
ilt7 antibody
ilt7
antibody
Prior art date
Application number
SI200632299T
Other languages
English (en)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co., Ltd. filed Critical Sbi Biotech Co., Ltd.
Publication of SI2913343T1 publication Critical patent/SI2913343T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
SI200632299T 2005-12-20 2006-12-20 Protitelo anti-ILT7 SI2913343T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
EP14186905.7A EP2913343B1 (en) 2005-12-20 2006-12-20 Anti-ILT7 antibody

Publications (1)

Publication Number Publication Date
SI2913343T1 true SI2913343T1 (sl) 2019-01-31

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200631864T SI2532681T1 (sl) 2005-12-20 2006-12-20 Protitelo proti-ILT7
SI200631608T SI1964852T1 (sl) 2005-12-20 2006-12-20 Proti-ilt7 protitelo
SI200632299T SI2913343T1 (sl) 2005-12-20 2006-12-20 Protitelo anti-ILT7

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200631864T SI2532681T1 (sl) 2005-12-20 2006-12-20 Protitelo proti-ILT7
SI200631608T SI1964852T1 (sl) 2005-12-20 2006-12-20 Proti-ilt7 protitelo

Country Status (29)

Country Link
US (6) US8084585B2 (sl)
EP (4) EP2913343B1 (sl)
JP (2) JP5020828B2 (sl)
KR (3) KR101526934B1 (sl)
CN (4) CN101379089B (sl)
AU (1) AU2006328470B2 (sl)
BR (1) BRPI0620141B1 (sl)
CA (2) CA2994756C (sl)
CY (3) CY1114227T1 (sl)
DK (3) DK2913343T3 (sl)
ES (3) ES2416716T3 (sl)
HK (4) HK1124347A1 (sl)
HR (2) HRP20130494T1 (sl)
HU (1) HUE039865T2 (sl)
IL (1) IL192266A (sl)
LT (1) LT2913343T (sl)
ME (1) ME02111B (sl)
MX (1) MX2008007682A (sl)
NZ (3) NZ569910A (sl)
PL (3) PL2532681T3 (sl)
PT (3) PT2532681E (sl)
RS (2) RS52860B (sl)
RU (2) RU2456298C2 (sl)
SG (2) SG10201602095PA (sl)
SI (3) SI2532681T1 (sl)
TR (1) TR201816574T4 (sl)
UA (1) UA97946C2 (sl)
WO (1) WO2007072866A1 (sl)
ZA (1) ZA200805850B (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
UA123257C2 (uk) 2010-02-24 2021-03-10 Іммуноджен, Інк. Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1
EP3085387A1 (en) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
UA113403C2 (xx) 2011-04-01 2017-01-25 Спосіб підвищення ефективності folr1 терапії раку
PT2828284T (pt) 2012-03-20 2019-06-17 Biogen Ma Inc Jcv neutralizando anticorpos
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
RS60217B1 (sr) 2012-08-31 2020-06-30 Immunogen Inc Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
MY176282A (en) 2013-08-30 2020-07-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
DK3218005T3 (da) 2014-11-12 2023-03-27 Seagen Inc Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
US10722592B2 (en) * 2015-03-18 2020-07-28 Seattle Genetics, Inc. CD48 antibodies and conjugates thereof
CA2989321A1 (en) * 2015-06-29 2017-01-05 Immunogen, Inc. Anti-cd123 antibodies and conjugates and derivatives thereof
CA2994888A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
MX2018006249A (es) * 2015-11-19 2018-11-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-emr2 y metodos de uso.
EP3407820A4 (en) 2016-01-26 2019-11-06 Cyberdontics, Inc. AUTOMATED DENTAL TREATMENT SYSTEM
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
IL261200B2 (en) * 2016-03-01 2023-03-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
EP3426298A4 (en) 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF
IL311675A (en) * 2016-04-04 2024-05-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
CN110913903B (zh) 2017-03-03 2024-03-01 思进股份有限公司 聚糖相互作用化合物和使用方法
KR20200042937A (ko) 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
AR113696A1 (es) * 2017-11-17 2020-06-03 Merck Sharp & Dohme Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
AU2018392717A1 (en) * 2017-12-20 2020-07-09 Albert Einstein College Of Medicine Antibodies to Centrin-1, methods of making, and uses thereof
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
WO2019217833A1 (en) * 2018-05-10 2019-11-14 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
CA3150428A1 (en) * 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
IL293572A (en) * 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins
AR121881A1 (es) 2020-04-20 2022-07-20 Genzyme Corp Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
EP4208122A1 (en) 2020-09-03 2023-07-12 Cyberdontics (USA), Inc. Method and apparatus for cna analysis of tooth anatomy
MX2023013015A (es) * 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
WO2024026388A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
CZ303155B6 (cs) * 1999-02-12 2012-05-09 The Scripps Research Institute Terapeutický prostredek pro lécení nádorové bunky v nádoru nebo metastázích nádoru a souprava jej obsahující
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
PT1446733E (pt) * 2001-10-13 2009-09-28 Asterion Ltd Polipéptidos contendo glicosilfosfatidilinositol
EP2316921B1 (en) * 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
JP4498136B2 (ja) 2002-08-01 2010-07-07 Ｓｂｉバイオテック株式会社 マウスインターフェロン産生細胞の検出方法
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
WO2005024043A2 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
ZA200805850B (en) 2009-04-29
NZ599683A (en) 2013-11-29
AU2006328470A1 (en) 2007-06-28
CN101379089A (zh) 2009-03-04
IL192266A0 (en) 2008-12-29
EP2913343A1 (en) 2015-09-02
AU2006328470B2 (en) 2012-08-16
CY1121294T1 (el) 2020-05-29
US20170204179A1 (en) 2017-07-20
AU2006328470A2 (en) 2008-10-09
CA2994756A1 (en) 2007-06-28
RU2008129715A (ru) 2010-01-27
EP2532681B1 (en) 2014-10-01
JP5020828B2 (ja) 2012-09-05
US20120135003A1 (en) 2012-05-31
HK1179638A1 (en) 2013-10-04
RU2456298C2 (ru) 2012-07-20
SI1964852T1 (sl) 2013-09-30
CN101379089B (zh) 2013-08-07
KR20080090430A (ko) 2008-10-08
RU2012112046A (ru) 2013-10-10
US20160130343A1 (en) 2016-05-12
PT2913343T (pt) 2018-11-21
CY1114227T1 (el) 2016-08-31
KR101624587B1 (ko) 2016-05-26
CN105111311A (zh) 2015-12-02
PT1964852E (pt) 2013-07-10
JP5420688B2 (ja) 2014-02-19
US20130259872A1 (en) 2013-10-03
CA2634116A1 (en) 2007-06-28
KR20140053232A (ko) 2014-05-07
TR201816574T4 (tr) 2018-11-21
EP2532681A1 (en) 2012-12-12
US20090280128A1 (en) 2009-11-12
US8084585B2 (en) 2011-12-27
BRPI0620141B1 (pt) 2024-04-30
KR20150031485A (ko) 2015-03-24
DK2913343T3 (en) 2018-11-26
UA97946C2 (ru) 2012-04-10
RU2599450C2 (ru) 2016-10-10
EP2913343B1 (en) 2018-08-08
WO2007072866A1 (ja) 2007-06-28
HRP20141226T1 (hr) 2015-02-27
US8470992B2 (en) 2013-06-25
KR101585532B1 (ko) 2016-01-14
SG10201602095PA (en) 2016-05-30
CA2994756C (en) 2020-10-27
CN103360492A (zh) 2013-10-23
HUE039865T2 (hu) 2019-02-28
ME02111B (me) 2015-10-20
CA2634116C (en) 2018-03-27
NZ616992A (en) 2015-07-31
EP1964852A4 (en) 2010-02-24
MX2008007682A (es) 2008-10-23
DK2532681T3 (en) 2015-01-05
EP3441403A1 (en) 2019-02-13
ES2526079T3 (es) 2015-01-05
PL2913343T3 (pl) 2019-03-29
HRP20130494T1 (en) 2013-08-31
HK1214603A1 (zh) 2016-07-29
LT2913343T (lt) 2018-11-26
SG170749A1 (en) 2011-05-30
CN110776566A (zh) 2020-02-11
RS52860B (en) 2013-12-31
PL1964852T3 (pl) 2013-09-30
SI2532681T1 (sl) 2015-03-31
JPWO2007072866A1 (ja) 2009-06-04
NZ569910A (en) 2012-06-29
CN105111311B (zh) 2019-10-18
JP2012143232A (ja) 2012-08-02
IL192266A (en) 2014-09-30
DK1964852T3 (da) 2013-07-08
PT2532681E (pt) 2014-12-23
BRPI0620141A2 (pt) 2011-11-01
EP1964852A1 (en) 2008-09-03
RS53752B1 (en) 2015-06-30
KR101526934B1 (ko) 2015-06-26
PL2532681T3 (pl) 2015-03-31
US20200339682A1 (en) 2020-10-29
ES2699428T3 (es) 2019-02-11
CY1116031T1 (el) 2017-01-25
HK1218126A1 (zh) 2017-02-03
HK1124347A1 (en) 2009-07-10
EP1964852B1 (en) 2013-04-17
ES2416716T3 (es) 2013-08-02

Similar Documents

Publication Publication Date Title
HK1218126A1 (zh) 抗體
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
GB0503546D0 (en) Antibody
SG10201404801YA (en) Monoclonal antibody
GB0517487D0 (en) Antibodies
EP1765396A4 (en) ANTIBODY
GB0615662D0 (en) Antibody
EP2011869A4 (en) NEW ANTI-CD98 ANTIBODY
GB0420466D0 (en) Anti-glucan antibodies
IL215527A (en) Methods will notice training
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0505489D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0418415D0 (en) Antibody
GB0500400D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0519883D0 (en) Antibodies
ZA200709879B (en) Improved immunoassay methods
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies